Evidence map›Paper›PMID 29116441›Full record

ArticleRheumatology international2018

Validation of the Toronto Psoriatic Arthritis Screen II (TOPAS II) questionnaire in a Turkish population.

Mehmet Tuncay Duruöz, Canan Şanal Toprak, Fırat Ulutatar

Registry-linked trialAbstract readValidation Study
PubMed Publisher
In one paragraph

Article in Rheumatology international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04277832 (Evaluation of a New Screening Tool), which is not on this map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04277832 completednot on this mapstarted 2020, after this paper: background citation

Evaluation of a New Screening Tool (TUPAST) for Psoriatic Arthritis in Turkish Psoriasis Population and Comparison With TOPAS 2 for Validation of TUPAST

TypeobservationalSponsorBezmialem Vakif UniversityRan2020 to 2021Enrolled200ConditionsPsoriasis, Psoriatic ArthritisArmsQuestionary
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mehmet Tuncay DuruözRheumatology Division, Department of Physical Medicine and Rehabilitation, Marmara University School of Medicine, Fevzi ÇakmakMahallesi, Tepe Sokak, No: 41, ÜstKaynarca, Pendik, Istanbul, Turkey.
Canan Şanal ToprakDepartment of Physical Medicine and Rehabilitation, Marmara University School of Medicine, Fevzi Çakmak Mahallesi, Tepe Sokak, No: 41, ÜstKaynarca, Pendik, Istanbul, Turkey. canansanal@hotmail.com.
Fırat UlutatarDepartment of Physical Medicine and Rehabilitation, Marmara University School of Medicine, Fevzi Çakmak Mahallesi, Tepe Sokak, No: 41, ÜstKaynarca, Pendik, Istanbul, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the TOPAS II questionnaire validation in a Turkish population.

methodsThe Turkish translation of ToPAS II was sent to us by the developer authors of the original index. Subjects were recruited from dermatology, physical medicine and rehabilitation, and rheumatology outpatient clinics. All patients' demographic parameters and ToPAS II questionnaire results were recorded. After patients completed the questionnaire they were assessed by a rheumatologist according to a standard protocol which includes a complete history, detailed physical examination, laboratory tests and CASPAR criteria. Receiver operating characteristics (ROC) assessed to obtain sensitivity and specificity of Turkish version of ToPAS II questionnaire.

resultsOne hundred and fifty subjects were recruited in the study. The mean age of subjects was 41.07 years (SD 12.59) and the 58% of subjects were female. There were 46 subjects from psoriasis group, 43 subjects from psoriatic arthritis (PsA) group, 41 subjects from physical medicine and rehabilitation group and 20 subjects from rheumatology (non-PsA) group. The area under the ROC curve was 0.99 which means as excellent predictor and optimum cut-off threshold to discriminate patients diagnosed with PsA was 8 according to this ROC curve analysis. The overall sensitivity and specificity based on cut-off threshold of 8, were 95.8 and 98%, respectively.

conclusionThe Turkish version of ToPAS II has high sensitivity and specificity. It is simple, not time consuming and useful tool to screen for PsA in both patients with and without psoriasis.

Indexed as

Surveys and QuestionnairesAdultArea Under CurveArthritis, PsoriaticCase-Control StudiesCultural CharacteristicsFemaleHealth StatusHumansMaleMiddle AgedPredictive Value of TestsPsoriasisReproducibility of ResultsROC CurveSeverity of Illness IndexPsoriasisPsoriatic arthritisScreening toolsValidation

Identifiers

PMID29116441

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.